The present invention relates to an inhaler device for delivering a dose of medicament in dry powder form from a container to a patient in need thereof. The inhaler comprises a swirl chamber in which particles of the medicament entrained in an airflow swirl upon inhalation thereby breaking up the agglomerates into finest dispersed powder.

A cartridge for use with a beneficial agent delivery device having a fillable reservoir. The cartridge includes a reconstitution, unit dose package having first and second compartments, and a fitment. The first compartment contains at least a first constintuent of the beneficial agent. The second compartment contains at least a second constituent of the beneficial agent. The fitment is disposed on the package for interfacing the package to the fillable reservoir.

The present invention relates to an inhalation device (1), to the use thereof, and to a kit comprising the inhalation device. The inhalation device (1) has an air inlet (14), an air outlet (15) designed as a mouthpiece or nosepiece, and a recess (17) which is designed to receive a container (2) with an inhalable substance. An air duct (L) extends from the air inlet (14) through the recess (17) to the air outlet (15). Moreover, the inhalation device (1) has at least one hollow mandrel (16, 16′) which protrudes into the recess (17) and from which at least one air delivery line (14′, 14″) extends to the air inlet (14) or at least one air outlet line (15′) extends to the air outlet (15). The inhalation device (1) is characterized in that the inhalation device (1) has two limbs (11, 12), each with a work end (11′, 12′) and with an actuation end (11″, 12″), wherein the limbs (11, 12) are connected by means of a joint (13) which lies between the work ends (11′, 12′) and the actuation ends (11″, 12″). Furthermore, the recess (17) is defined between the mutually facing sides of both limbs (11, 12) at the work ends (11′, 12′), wherein the at least one hollow mandrel (16, 16′) is arranged inside the recess (17) on one of the mutually facing sides of both limbs (11, 12). The air inlet (14) and the air outlet (15) are arranged at the work end (11′, 12′) on a side, directed away from the recess (17), of at least one of the limbs (11, 12).

A method of delivering a substance, such as one or more of a triptan, a nasal steroid or carbon dioxide gas, to the nasal cavity of a subject, in particular for the treatment of headaches, for example, migraine, or rhinosinusitis, for example, chronic rhinosinusitis, optionally with polyps, the method comprising the steps of fitting a nosepiece to one nostril of the subject, delivering the substance through the nosepiece to the posterior region of the nasal cavity of the subject.

A device for inhaling an active agent is provided that can be moved from a first configuration to a second configuration. The device comprises two flexible substrates and a membrane (40) located between the two flexible substrates, and the two flexible substrates being connected at two opposing edges and unconnected at two further opposing edges. An active agent provided on the membrane may be inhaled by a user when the device is in the second configuration.

Adherence monitors are disclosed, incorporating cap removal sensors together with a determined time period in order to determine that a dose of medicament has been dispensed. In another form, cap removal data is combined with acoustic data to determine that a dose of medicament has been dispensed. Several specific structural arrangements are also disclosed.

An inhaler article includes a body extending along a longitudinal axis from a mouthpiece end to a distal end and a capsule cavity defined within the body. The capsule cavity has a length extending along the longitudinal axis. A mouthpiece air channel extends from the capsule cavity to the mouthpiece end. An end cap is disposed within the distal end and extends to the capsule cavity. The end cap includes an air channel extending from the end cap distal end to the end cap inner end. A capsule is disposed within the capsule cavity and has a capsule length. The capsule length is in a range from about 25% to about 99% of the cavity length, or about 50% to about 95% of the cavity length, or about 70% to about 90% of the cavity length, or from about 75% to about 85% of the cavity length, or about 80% of the cavity length.

A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.

Medical devices and methods of treating subjects using such medical devices are described. The medical device may include a housing with at least two chambers including a first chamber adjacent to a second chamber; a barrier between the first chamber and the second chamber; and a soft, flexible base. The first and second chambers may be airtight, the barrier configured to establish fluid communication between the first chamber and the second chamber upon an application of force to the barrier.

Provided is a system (10) for determining a probability of an asthma exacerbation in a subject. The system comprises an inhaler (100) for delivering a rescue medicament to the subject. The inhaler has a use-detection system (12B) configured to determine a rescue inhalation performed by the subject using the first inhaler. A sensor system (12A) is configured to measure a parameter relating to airflow during the rescue inhalation. The system further comprises a processor (14) configured to determine a number of the rescue inhalations during a first time period, and receive the parameter measured for at least some of the rescue inhalations. The processor determines, using a weighted model, the probability of the asthma exacerbation based on the number of rescue inhalations and the parameters.

The model is weighted such that the number of rescue inhalations is more significant in the probability determination than the parameters.